Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest Update

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 134,600 shares, an increase of 102.7% from the December 31st total of 66,400 shares. Based on an average trading volume of 3,450,000 shares, the short-interest ratio is currently 0.0 days. Currently, 2.2% of the shares of the company are short sold.

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ CYCC traded up $0.01 during midday trading on Wednesday, reaching $0.37. The stock had a trading volume of 48,491 shares, compared to its average volume of 7,043,026. The firm has a market cap of $2.30 million, a price-to-earnings ratio of -0.04 and a beta of 0.35. Cyclacel Pharmaceuticals has a twelve month low of $0.31 and a twelve month high of $4.00. The company’s 50 day moving average price is $0.37 and its 200 day moving average price is $0.83.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.36. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million.

Analysts Set New Price Targets

A number of brokerages have recently commented on CYCC. StockNews.com began coverage on shares of Cyclacel Pharmaceuticals in a research report on Sunday. They issued a “sell” rating for the company. Roth Capital cut shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.